Mellitus

About:

Mellitus develops a diabetes detection and monitoring device to detect gestational diabetes.

Website: http://www.mellitusllc.com/

Top Investors: Broadview Ventures

Description:

Mellitus develops a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis, and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.

Total Funding Amount:

$13.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2011-01-01

Founders:

Jose A. Halperin, Joyce Lonergan, Michael Chorev

Number of Employees:

1-10

Last Funding Date:

2019-05-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai